VivoSeq
Neurology

Polyneuropathy

26

Pipeline Programs↗

2

Active Trials↗

22

Companies Involved↗

Polyneuropathy is an emerging landscape with 26 programs across 22 companies. The most active players are Tonghua Anrate Biopharmaceutical Co., Ltd., SOM Innovation Biotech SA, Eli Lilly. 7 therapies are approved with 7 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

50/100

Pipeline Velocity

6/100

Mech. Concentration

11/100

Completion Rate

90/100

Attrition Rate

7/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

T

Tonghua Anrate Biopharmaceutical Co., Ltd.

1 program

Phase 1S

SOM Innovation Biotech SA

1 program

Phase 2Eli Lilly logo

Eli Lilly

1 program

Phase 2Johnson & Johnson logo

Johnson & Johnson

1 program

Phase 2Pfizer logo

Pfizer

1 program

Phase 3N

NovaMed Pharmaceuticals Inc.

1 program

Phase 3

Pipeline

Programs by Phase

Preclinical4

Patisiran

Alnylam Pharmaceuticals

HB-Admscs

Hope Biosciences Research Foundation

Sida Cordifolia Roots

Rosenberg European Academy of Ayurveda

Phyllanthus Niruri

Rosenberg European Academy of Ayurveda

Phase 13

Human Albumin

Tonghua Anrate Biopharmaceutical Co., Ltd.

Tangbi (prescription)

Guang'anmen Hospital of China Academy of Chinese Medical Sciences

Igm-Enriched Intravenous Immunoglobulins

Medical University of Vienna

Phase 25

Topiramate

Wim Janssens

LY3848575

Eli Lilly

Daratumumab and Hyaluronidase-Fihj

Johnson & Johnson

WST-057

WinSanTor, Inc

SOM0226

SOM Innovation Biotech SA

Phase 37

Rituximab

Roche

Inotersen

Akcea Therapeutics

Eplontersen

AstraZeneca

Lipoic Acid

NovaMed Pharmaceuticals Inc.

Fx-1006a

Pfizer

Approved7

Phenytoin

Viatris Specialty LLC

Escitalopram

AbbVie

Levetiracetam

UCB

Pregabalin

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Tafamidis

K-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc.

Analysis

Modality Breakdown

84%

Small molecule

21 of 25 classified programs — the dominant modality here.

16%ALL OTHERSRNA therapy312%Monoclonal antibody14%

Small molecule leads; the ring shows all 25 classified programs, each share of the total. Modality classified for 100% of 26 pipeline programs.

Analysis

Trial Status

27

clinical trials

Completed18 · 67%
Unknown status4 · 15%
Active, not recruiting1 · 4%
No longer available1 · 4%
Terminated1 · 4%
Recruiting1 · 4%
Other1 · 4%

Clinical Trials

Trial Activity

27 trials

To Evaluate the Efficacy and Safety of Tafamidis Meglumine Soft Capsules in the Treatment of Adult Patients With Transthyretin Amyloid Polyneuropathy
Recruiting·Qilu Pharmaceutical Co., Ltd. logoQilu Pharmaceutical Co., Ltd.·Phase 4·NCT06940336·15 enrolled
A Study to Assess the Long-Term Safety and Efficacy of Eplontersen (Formerly Known as ION-682884, IONIS-TTR-LRx and AKCEA-TTR-LRx) in Patients With Hereditary Transthyretin-Mediated Amyloid Polyneuropathy
Active, not recruiting·Ionis Pharmaceuticals logoIonis Pharmaceuticals·Phase 3·NCT05071300·151 enrolled
Extension Study Assessing Long Term Safety and Efficacy of IONIS-TTR Rx in Familial Amyloid Polyneuropathy (FAP)
Completed·Ionis Pharmaceuticals logoIonis Pharmaceuticals·Phase 3·NCT02175004·135 enrolled
Evaluating the Efficacy and Safety of Oral Ranirestat (40 and 80 mg) in Mild to Moderate Diabetic Sensorimotor Polyneuropathy
Completed·Eisai logoEisai·Phase 2/3·NCT00927914·800 enrolled
NEURO-TTRansform: A Study to Evaluate the Efficacy and Safety of Eplontersen (Formerly Known as ION-682884, IONIS-TTR-LRx and AKCEA-TTR-LRx) in Participants With Hereditary Transthyretin-Mediated Amyloid Polyneuropathy
Completed·Ionis Pharmaceuticals logoIonis Pharmaceuticals·Phase 3·NCT04136184·168 enrolled
A Study of Phyllanthus Niruri and Sida Cordifolia in Diabetic Peripheral Polyneuropathy
Completed·RRosenberg European Academy of Ayurveda·N/A·NCT02107469·98 enrolled
The Effect Of Tafamidis Meglumine In Transthyretin Amyloid Polyneuropathy Patients
Completed·Pfizer logoPfizer·Phase 4·NCT04828993·15 enrolled
A Multicenter Observational Study to Evaluate the Effectiveness of Patisiran in Patients With Polyneuropathy of ATTRv Amyloidosis With a V122I or T60A Mutation
Completed·Alnylam Pharmaceuticals logoAlnylam Pharmaceuticals·N/A·NCT04201418·67 enrolled
Efficacy and Safety of Inotersen in Familial Amyloid Polyneuropathy
Completed·Ionis Pharmaceuticals logoIonis Pharmaceuticals·Phase 2/3·NCT01737398·173 enrolled
A Study To Evaluate The Effect Of Topiramate On Clinical And Electrophysiological Parameters In Subjects With Diabetic Peripheral Polyneuropathy
Completed·Johnson & Johnson Pharmaceutical Research & Development, L.L.C. logoJohnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 2·NCT00231673·72 enrolled
Phase III Randomized, Double-Blind, Placebo-Controlled Study of 3,4-Diaminopyridine for Demyelinating Polyneuropathy
Completed·NNational Center for Research Resources (NCRR)·Phase 3·NCT00004939·34 enrolled
Escitalopram as a Treatment for Pain in Polyneuropathy
Completed·OOdense University Hospital·Phase 4·NCT00162968·50 enrolled
A Study to Determine if Levetiracetam Will Assist Those Suffering From Chronic Idiopathic Axonal Polyneuropathy.
Completed·VVanderbilt University·Phase 2·NCT00156689·30 enrolled
A 16-Week Study of Pirenzepine or Placebo to Treat HIV-Associated Distal Sensory Polyneuropathy in Patients With HIV
Completed·WWinSanTor, Inc·Phase 2·NCT05005078·16 enrolled
Safety and Efficacy of AS-3201 in the Treatment of Diabetic Sensorimotor Polyneuropathy
Completed·SSumitomo Pharma Co., Ltd.·Phase 3·NCT00101426·500 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)